Buy Liraglutide 18mg

Liraglutide was the first GLP-1 receptor agonist approved for weight management (as Saxenda, 3mg/day). While semaglutide and tirzepatide have superseded it in efficacy, liraglutide has the most extensive long-term safety data of any GLP-1 compound — with 15+ years of clinical experience and the SCALE and LEADER trials providing robust cardiovascular and metabolic outcome data.

▸Why Some Prefer Daily Liraglutide

Weekly GLP-1 injections (semaglutide, tirzepatide) produce higher peak concentrations that can intensify side effects during the first 24-48 hours post-injection. Daily liraglutide maintains more stable plasma levels with lower peak-to-trough variation, which some users find produces more consistent appetite suppression with less nausea concentration.

▸SCALE Obesity Trial Results

At 3mg/day, liraglutide produced 8% average body weight reduction at 56 weeks in the SCALE Obesity trial — less than semaglutide's 15-20% but still clinically significant. The cardiovascular benefits from LEADER (13% reduction in major cardiac events) have been confirmed in follow-up analyses.

▸Reconstitution and Daily Protocol

An 18mg vial reconstituted with 3.6mL bacteriostatic water yields a 5mg/mL concentration. At 1.2mg/day (a common starting dose), draw 0.24mL daily. At the maximum 3mg/day dose, draw 0.6mL daily, and the vial covers 6 days at maximum dose or 15 days at starting dose.